Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M110703200 on March 6, 2002

J. Biol. Chem., Vol. 277, Issue 20, 17883-17891, May 17, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/20/17883    most recent
M110703200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakagawa, J.
Right arrow Articles by Kitamura, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakagawa, J.
Right arrow Articles by Kitamura, K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular Characterization of Mammalian Dicarbonyl/L-Xylulose Reductase and Its Localization in Kidney*

Junichi NakagawaDagger §, Syuhei Ishikura, Jun AsamiDagger , Tomoya Isaji, Noriyuki Usami, Akira Hara, Takanobu SakuraiDagger , Katsuki TsuritaniDagger , Koji OdaDagger , Masayoshi TakahashiDagger , Makoto YoshimotoDagger , Noboru OtsukaDagger , and Kunihiro KitamuraDagger

From the Dagger  Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama-shi, Saitama 330-8530, and the  Biochemistry Laboratory, Gifu Pharmaceutical University, Gifu 502-8585, Japan

Received for publication, November 7, 2001, and in revised form, March 5, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this report, we first cloned a cDNA for a protein that is highly expressed in mouse kidney and then isolated its counterparts in human, rat hamster, and guinea pig by polymerase chain reaction-based cloning. The cDNAs of the five species encoded polypeptides of 244 amino acids, which shared more than 85% identity with each other and showed high identity with a human sperm 34-kDa protein, P34H, as well as a murine lung-specific carbonyl reductase of the short-chain dehydrogenase/reductase superfamily. In particular, the human protein is identical to P34H, except for one amino acid substitution. The purified recombinant proteins of the five species were about 100-kDa homotetramers with NADPH-linked reductase activity for alpha -dicarbonyl compounds, catalyzed the oxidoreduction between xylitol and L-xylulose, and were inhibited competitively by n-butyric acid. Therefore, the proteins are designated as dicarbonyl/L-xylulose reductases (DCXRs). The substrate specificity and kinetic constants of DCXRs for dicarbonyl compounds and sugars are similar to those of mammalian diacetyl reductase and L-xylulose reductase, respectively, and the identity of the DCXRs with these two enzymes was demonstrated by their co-purification from hamster and guinea pig livers and by protein sequencing of the hepatic enzymes. Both DCXR and its mRNA are highly expressed in kidney and liver of human and rodent tissues, and the protein was localized primarily to the inner membranes of the proximal renal tubules in murine kidneys. The results imply that P34H and diacetyl reductase (EC 1.1.1.5) are identical to L-xylulose reductase (EC 1.1.1.10), which is involved in the uronate cycle of glucose metabolism, and the unique localization of the enzyme in kidney suggests that it has a role other than in general carbohydrate metabolism.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Carbonyl compounds are routinely generated in the course of metabolic reactions and by oxidative stresses in a variety of biological systems. When two carbonyl groups juxtapose on a carbon chain, the reactivity of each carbonyl group tends to be elevated, and those compounds with such alpha -dicarbonyl groups are known to be prone to conversion into advanced glycation end-products (AGEs).1 AGEs are a group of insoluble complex compounds that frequently accumulate in the plasma proteins and tissues of diabetic subjects and are also associated with renal failure regardless of diabetic background (1-3). Advanced aging also accounts for the triggering of AGE accumulation (4). The starting compounds are assumed to originate from carbohydrates such as glucose and fructose, or from lipid compounds, which then undergo a non-enzymatic Maillard reaction followed by a series of as yet unidentified non-enzymatic and enzymatic reactions, via major intermediate compounds harboring an alpha -dicarbonyl group in their molecules (1, 3-5). The AGEs subsequently stimulate a group of scavenger receptors called RAGEs, leading to an aberrant production of inflammatory cytokines (6, 7). In addition, by cross-linking proteins, especially those with long lives such as collagen, laminin, and other extracellular matrix proteins, AGEs may cause sclerotic disorders in the blood vessels and in tissues (8). This may eventually lead to the progression of diabetic retinopathy (9).

The potential relevance of aldose reductase and aldehyde reductase in detoxifying such dicarbonyl compounds has been documented (10, 11); however, a question remained of whether there exists one or more reductases working specifically in the renal system. Supporting this notion, it is widely noted that renal failure is one of the major causes accounting for the accumulation of AGEs on plasma proteins and tissues, most prominently in the tubules of the nephron (12). Accordingly, it has been postulated that the function of the renal tubules is pivotal to the clearance of AGEs and their precursors, dicarbonyl compounds (13).

In the course of screening potential renal therapeutic target genes, we have constructed a 3'-directed cDNA library from materials enriched with renal tubules and glomeruli of mouse kidney to generate a gene expression profile of the kidney. Following large-scale sequencing of about 1000 random cDNA clones, a non-biased representation of the mRNA population in the kidney was obtained. A data base survey of the sequences revealed that one of these candidate clones displayed significant sequence homology with mouse lung carbonyl reductase (MLCR (14)), which is a member of the short-chain dehydrogenase/reductase (SDR) superfamily (15). This inspired us to further investigate its possible involvement in renal carbonyl detoxification. Subsequent PCR-based homologue cloning yielded the isolation of human, hamster, rat, and guinea pig counterparts of the murine cDNA. The enzymatic characterization of the recombinant proteins expressed from the cDNAs of the five species shows that they turn out to be reductases that are specific for dicarbonyl compounds, i.e. diacetyl reductase (EC 1.1.1.5). Surprisingly, the recombinant proteins also displayed significant reductase activity toward L-xylulose, and the identity of diacetyl reductase with L-xylulose reductase (EC 1.1.1.10) has been demonstrated by co-purification of the two enzyme activities from guinea pig liver, in which L-xylulose reductase was first identified (16). Based on these findings, we designated the protein encoded in the isolated cDNA as dicarbonyl/L-xylulose reductase (DCXR). Furthermore, we report the distribution of DCXR in the tissues of the five mammals investigated as well as its immunohistochemical localization in rat and mouse kidneys.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Library Construction and cDNA Cloning-- Fractions enriched with glomeruli and renal tubules were prepared from male BALB/c mice using magnetic beads (Dynabeads M280 and M450, Dynal A.S., Oslo, Norway). Heparin (10 units/100 µl) was injected into the tail vein of a mouse, and 0.2 ml of a Dynabeads M280 suspension (6×108/ml), followed by 0.2 ml of a Dynabeads M450 suspension (4×108/ml), was injected through the renal afferent arteriole after a ventral opening operation. The kidney was removed and minced, and then the glomerular fraction was collected following the sieving selection (17). The tissue fraction containing the Dynabeads was separated from the other tissues by magnetic force to obtain the fraction enriched with glomeruli and renal tubules. The collected fragments were examined under a light microscope to confirm the enrichment of glomeruli (roughly 7.5 × 103 glomeruli and 4 × 103 renal tubule fragments in a 0.1-ml suspension). The extraction of RNA, the synthesis of cDNA followed by its MboI digestion, the construction of the cDNA library, and the subsequent body mapping analysis were performed as described previously (18, 19), and other miscellaneous handling of DNA and protein was performed according to general procedures (20). The short cDNA fragments (average size of 256 bp) generated by the MboI digestion were sequenced using a PRIM 377 DNA sequencer (Applied Biosystems, Foster City, CA). A cDNA clone that showed high expression frequency (3 out of 958 clones) was subjected to further cloning of the cDNA containing a full-length open reading frame. The complete cDNA was isolated by PCR using a forward primer (5'-TGCTGCGAGAAGACGACAGAAT-3') in the CapFinder cDNA library construction kit (CLONTECH, Palo Alto, CA) and a reverse primer (5'-AGTGGTCATGCCACTCCGGTTGCTCAG-3'), which was designed based on the sequence of one DCXR cDNA fragment containing a putative 3'-untranslated sequence. The sequence of this clone was determined by repeating PCR using a set of primers, Expf and Expr (see Table I), and then sequencing of the amplified products.

The human counterpart was cloned by reverse transcription-PCR (RT-PCR). First-strand cDNA was prepared from human kidney mRNA (CLONTECH) using the SMART PCR library construction kit (CLONTECH) with the oligomer hu-1f as a cap finder and then was subjected to PCR with the primers hu-2f (with affinity to the cap-binding site of the single-strand cDNA) and the gene-specific primer, hu-3r. The hu-3r was designed to anneal the sequence outside the putative open reading frame based on a human Expressed Sequence Tag (EST) sequence similar to the mouse DCXR cDNA (see Table I). Finally, the open reading frame was amplified with a pair of primers, hu-4f and hu-5r, containing recognition sites for restriction enzymes for the later subcloning process. The cDNAs for rat, hamster, and guinea pig DCXRs were isolated from the total RNA preparations of rat kidney and livers of hamsters and guinea pigs by RT-PCR and subsequent RACE (rapid amplification of cDNA ends). The amplification of the cDNAs for the DCXRs of the three species by PCR was achieved with a set of primers, Expf and Expr, which correspond to nucleotides 1-18 and 717-735, respectively, of the cDNA for mouse DCXR. The 3'- and 5'-ends of the cDNAs were generated by using 3'- and 5'-RACE kits (Invitrogen, Carlsbad, CA) and the gene-specific primers (see Table I). The cDNAs were subcloned into the sequencing vector, pGEMT (Promega, Madison, WI) or pCR2.1 (Invitrogen) and sequenced as described above.

Expression and Purification of Recombinant DCXR-- To express the recombinant human and rodent DCXRs, the coding regions of the cDNAs were amplified by PCR using the following sets of primers containing restriction enzyme cutting sites (see Table I). The PCR primers were hu-Nf and hu-Kr (for human DCXR cDNA), ra-Nf and ha-Kr (for hamster DCXR cDNA), and ra-Nf and Expr (for other rodent DCXR cDNAs). Although the sequences of the primers were different by one or two nucleotides from those of the corresponding regions of the rodent DCXR cDNAs, the deduced amino acids were not changed. The amplified DNA fragments were digested with the restriction enzymes, then ligated into pRset plasmids. DNA sequencing confirmed that no unintended base substitution had been incorporated in the coding regions of the expression plasmids.

Expression of the recombinant DCXRs in Escherichia coli BL21(DE3) (Stratagene, La Jolla, CA) and preparation of the cell extract were performed as described previously (14). The recombinant DCXRs were purified from the cell extract according to the procedures for purification of hamster liver diacetyl reductase (21), except that a Matrex Red A (Amicon, Beverly, MA) column was used instead of the Blue-Sepharose column. The adsorbed DCXR was eluted from the Matrex Red A column with buffer containing 0.5 mM NADP+. It should be noted that, because the activities of the recombinant rodent DCXRs were gradually inactivated below 10 °C, the chromatography was carried out at room temperature (RT, 20-25 °C), and the buffers were supplemented with 20% (v/v) glycerol to prevent cold inactivation. Recombinant MLCR and hamster sperm 26-kDa protein, P26h, were prepared as described in Refs. 14 and 22, respectively.

Purification of Diacetyl Reductase and L-Xylulose Reductase-- Hamster liver diacetyl reductase was purified as described in Ref. 21. L-Xylulose reductase was purified from male Hartley guinea pig livers (50 g) essentially according to the same procedures employed for the purification of hamster diacetyl reductase. Since guinea pig L-xylulose reductase was also unstable at 4 °C, all the chromatography steps were performed at RT using the buffers containing 20% (v/v) glycerol, and the following modifications were made. 1) The enzyme was eluted from the DEAE-Sephacel column with 30 mM NaCl in 10 mM Tris-HCl, pH 8.0, containing 1 mM EDTA and 2 mM 2-mercaptoethanol after washing the column with buffer containing 10 mM NaCl. 2) The Blue-Sepharose column was washed with buffer A (10 mM Tris-HCl, pH 8.5, containing 2 mM 2-mercaptoethanol), and then the enzyme was eluted with buffer A containing 0.5 mM NADP+.

Enzyme Assay-- The standard reaction mixture for the reductase activity consisted of 0.1 M potassium phosphate buffer, pH 6.0, 0.1 mM NADPH, substrate and enzyme, in a total volume of 2.0 ml. Diacetyl (5 mM) was employed as the substrate for DCXR and hamster liver diacetyl reductase, and 1 mM L-xylulose was used as the substrate for guinea pig liver L-xylulose reductase. The dehydrogenase activities of the enzymes were measured in 0.1 M potassium phosphate buffer, pH 7.0, containing 0.25 mM NADP+ and alcohol substrate. Sugars were obtained from Sigma-Aldrich (St. Louis, U.S.A.) and Fluka Chemie (Buchs, Switzerland), except that 3-deoxyglucosone was a gift from Dr. V. Monnier (Case Western Reserve University). One unit of enzyme activity was defined as the amount of enzyme that catalyzes the reduction and formation of 1 µmol of NADPH per min at 25 °C.

A kinetic analysis of the enzyme reaction was carried out in 0.1 M potassium phosphate buffer, pH 7.0, at five different concentrations of the substrate or coenzyme to obtain apparent Km and Vmax values. Kinetic studies in the presence of inhibitors were carried out in a similar manner. In addition to the kinetic constants, the inhibition constant, Ki, was calculated by using the appropriate programs of the ENZFITTER (Biosoft, Cambridge, UK). All standard errors of fits were less than 15%.

Cold inactivation experiments were carried out as follows. The enzyme (0.4 mg/ml) was dialyzed against 0.1 M potassium phosphate buffer, pH 7.0, at 25 °C for 8 h, and then diluted with 9 volumes of the buffer containing 1 mg/ml bovine serum albumin. The enzyme solution was incubated in an ice bath or at various temperatures, and 50-µl aliquots of the solution were taken at different times and analyzed for the diacetyl reductase activity as described above.

Tissue Distribution Analyses-- First-strand cDNAs were prepared from the total RNAs (1 µg samples) of mouse, rat, hamster, guinea pig and human tissues (Sawady, Tokyo, Japan) as described above. The cDNAs were subjected to PCR in a 20-µl reaction mixture containing Taq DNA polymerase (1 unit) and the following primers (1 µM). The forward and reverse primers for the amplification of rodent DCXR cDNAs were Expf and Expr, respectively, which did not amplify the cDNAs for MLCR and P26h, and the respective primers for that of human DCXR cDNA were hu-Nf and hu-Kr. cDNAs for human, mouse and rat beta -actins were also amplified as internal controls with the specific primers that were obtained from Takara and Toyobo (Osaka, Japan).

Antibody Production and Western Blot Analysis-- To prepare an antibody against murine DCXR, a peptide corresponding to positions 38-51 of the enzyme sequence was synthesized, conjugated to Keyhole Limpet Hemocyanin, and injected subcutaneously into rabbits (20). In addition, a polyclonal antibody against recombinant His-tag human DCXR was also raised in rabbits. To express the (His)6-tagged human DCXR, we amplified the cDNA insert using the primers, hu-4f and hu-5r (see Table I). The obtained PCR fragments were digested with the restriction enzymes, then ligated into expression plasmids, pTrcA (Invitrogen). The recombinant enzyme was expressed in E. coli BL21(DE3) cells, and purified using nickel nickel-nitrilotriacetic acid-agarose (Qiagen, Santa Clarita, CA) according to the manufacturer's instructions. The antibodies in the antisera were purified first on a protein-A column and subsequently with an affinity column cross-linked with the corresponding peptide or recombinant protein (20). The anti-mouse DCXR antibody specifically reacted with the mouse and rat DCXRs, whereas the anti-human DCXR antibody cross-reacted with the DCXRs of human and all the rodent species.

The tissues of mice, rats, hamsters and guinea pigs were homogenized with 4 volumes of 0.25 M sucrose at 4 °C, and the homogenates were centrifuged at 105,000 × g for 1 h. The supernatant fractions (each comprising 20 µg of protein) and the other human tissue samples (each comprising 40 µg of protein, CLONTECH) were subjected to Western blot analysis (20) using the above antibodies

Immunohistochemical Analysis-- The kidneys removed from Sprague-Dawley rats (20 weeks, male) and BALB/c mice (10 weeks, female) were fixed in neutralized 10% (v/v) formalin, embedded in paraffin, and sectioned at 3 µm. For immunohistochemistry, these sections were stained by the avidin-biotin-peroxidase complex method (23). The primary and secondary biotinylated antibodies for DCXR staining were the anti-mouse DCXR antibody (10 µg/ml in PBS) and a goat anti-rabbit immunoglobulin (IgG) antibody (10 µg/ml, Vector Laboratories, Burlingame, CA), respectively. The sections were incubated with the primary antibody for 16 h at 4 °C, then with the secondary antibody for 1 h at RT, and with avidin-biotinylated peroxidase complex (Vector Laboratories) for 1 h. The peroxidase activity was visualized with the AEC Chromogen kit (Sigma Immunochemicals) and counterstained with hematoxylin. For immunofluorescence microscopy, the primary and secondary antibodies for DCXR staining were the same as those used in the immunohistochemistry. Subsequently the sections were incubated with Cy2-labeled streptavidin (100×, Amersham Biosciences, Inc., Buckinghamshire, UK) for 1 h. For double immunofluorescence microscopy, AGEs were stained using a mouse monoclonal anti-AGE antibody (2 µg/ml, Clone 6D12, Wako Pure Chemicals, Osaka, Japan) and Cy2-labeled goat anti-mouse IgG antibody (10 µg/ml, Amersham Biosciences, Inc.) as the primary and secondary antibodies, respectively, while DCXR was stained with the Cy3-labeled streptavidin (100×, Amersham Biosciences, Inc.). Stained sections were examined using the Axiolan2 microscope (Carl Zeiss, Jena, Germany).

Immunoelectron Microscopy-- Under anesthetization with ether, C57BL/6 mice were flushed with PBS from the left ventricle to remove the blood, immediately perfused for fixation with 4% (w/v) paraformaldehyde and 0.2% (v/v) glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.3, for 30 min. The kidneys were dissected out and immersed in the same fixative for 1 h at 4 °C. The fixed samples were embedded in LR white resin. Then 70-nm Ultrathin sections were incubated at RT with the anti-mouse DCXR antibody (5 µg/ml in PBS) for 1.5 h, and subsequently with 10-nm gold-conjugated anti-rabbit IgG antibody (×50 dilution in 1% bovine serum albumin-Tris buffered saline, British Biocell International, Cardiff, UK) for 2 h. The sections were stained with uranyl acetate and examined by a transmission electron microscope, Model H-7500 (Hitachi, Tokyo, Japan). Control staining was conducted by using normal rabbit IgG (5 µg/ml).

Other Methods-- The protein concentration was determined by the method of Bradford (24). SDS-PAGE on 12.5% (w/v) slab gels (25) and analytical gel filtration on a Superdex 200 HR column (14, 22) were carried out as described previously. Protein sequence determination of the peptides derived by digestion of the purified liver enzymes with lysylendopeptidase was performed as described in Ref. 11.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cloning of cDNA Species for Rodent and Human DCXRs-- In the initial stage of this study, the aim of the cloning scheme was to isolate genes potentially involved in the major renal functions or highly expressed in the kidney, in an attempt to screen potential renal therapeutic target genes. Therefore, candidate genes were screened from a cDNA library prepared from the tissue fractions enriched in glomeruli and renal tubules of C57BL/6 mouse kidney. The library was composed of relatively short 3'-directed DNA fragments (theoretical average size, 256 base pairs) generated by MboI digestion of the cDNA to ensure its non-biased complexity. Following large-scale DNA sequencing of about 1,000 cDNAs, the library was found to contain 958 clones, three of which were from a cDNA species that has not been reported. The cDNA contained a 735-bp open reading frame, in which a polypeptide of 244 amino acids with a molecular weight of 25,744 Da is encoded (Fig. 1). We designated the protein as DCXR based on its enzymatic characteristics described below.


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 1.   Alignment of deduced amino acid sequences of MLCR, P26h, and mammalian DCXRs. Identical residues between mouse DCXR and the other proteins are denoted by hyphens. Several conserved residues among the SDR family enzymes are depicted in boldface letters (for details see "Results"). The sequences of the peptides derived from the purified enzymes from hamster and guinea pig livers are underlined in the deduced sequences of the respective animals. Abbreviation and accession numbers of DCXRs: mouse (Mo), D89656; Rat (Ra), AB061719; hamster (Ha), AB045204; guinea pig (Gp), AB061720; human (Hu), AB013846.

To investigate whether other mammalian kidneys contain DCXR, we analyzed sequences deposited in the EST division of the GenBankTM data base, and found several human (AF113123) and rat (AI16935 and BI283134) EST sequences similar to the cDNA for mouse DCXR. Because the human EST sequences corresponded to both 5'- and 3'-noncoding regions of the mouse DCXR cDNA, primers were designed to anneal the non-coding regions of human DCXR cDNA, and the cDNA (806 bp) was isolated by RT-PCR and RACE from the human kidney mRNA preparation. RT-PCR with the primers, Expf and Expr, amplified cDNA fragments of about 735-bp from the total RNA of rat kidney, and the sequence (879 bp) of the full-length cDNA for rat DCXR was determined by 3'- and 5'-RACE with the gene-specific primers (Table I). Each of the cDNA species contained a stop codon (TGA or TAA), a polyadenylation signal sequence, the poly(A) sequence, and the characteristic sequence around the first ATG codon. The cDNA species for hamster and guinea pig DCXRs could also be isolated by RT-PCR and RACE from the total RNA samples of the livers, because the recombinant DCXRs exhibited the activities of diacetyl reductase and L-xylulose reductase (as described below), which have been purified from the livers of the two animals (21, 26).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Nucleotide sequences of the primers used in this study
The restriction enzyme cutting site in each sequence is shown in italic, and the initiation and stop codons are indicated in bold. The nucleotide positions correspond to those of the cDNA species isolated, and Race-1r through -5r and Race-2f through -5f were the primers used in the 5'-RACE and 3'-RACE, respectively.

Homology Studies-- The amino acid sequences deduced from the cDNA species for the DCXRs of the five mammals are aligned in Fig. 1. A homology of over 90% was observed among the DCRXs of the rodent species, and a homology of about 85% was observed between the rodent and human proteins. A homology search against entries in the protein data bases provided by the GenomeNet data base service (Kyoto University, Kyoto, Japan) sorted out large numbers of SDR family proteins, of which human sperm 34-kDa protein, P34H (27), MLCR (14), and P26h (28) showed high sequence identity (>63%) with all the DCXRs, in contrast to less than 30% identity between the DCXRs and other members of this family. The sequence of human DCXR is identical to that of P34H (27), except for one amino acid substitution (G239R) due to one of two different nucleotides at positions 381 and 715, but the enzymatic function of P34H is unknown. The two consensus sequences, i.e., N-terminal GXXXGXG and YXXXK at positions 149-153, of the SDR family proteins (15), and several residues in the coenzyme-binding (Lys-17, Ile-19, Leu-61, Ala-84, and Val-182), catalytic mechanism (Ser-136), and subunit interaction (Arg-203) of MLCR (29) are conserved in the sequences of the five DCXRs and P26h. However, Arg-39, which is a determinant for the NADP(H) specificity of MLCR (30), is present in the DCXRs, but not in P26h that exhibits NAD(H)-dependent 3alpha -hydroxysteroid dehydrogenase activity distinct from the substrate specificity of MLCR (22). Two regions (at positions 136-148 and 183-202) are the most different between the DCXRs and MLCR or P26h and include Phe-143, Leu-146, and Val-190, which may interact with the product in the ternary complex of MLCR crystal (29). The above sequence similarity and differences imply that DCXR is an NADP(H)-preferring oxidoreductase with substrate specificity that differs from that of MLCR and P26h and caused us investigate enzymatic activity with the recombinant protein.

Enzymatic Characterization of DCXR-- The extracts of E. coli cells transfected with the pRset plasmids harboring the cDNAs for the DCXRs of the five species exhibited NADPH-linked reductase activity for dicarbonyl compounds, such as diacetyl and 3,4-hexanedione, but they did not reduce 4-nitroacetophenone and 2-butanone, which are representative substrates of MLCR and P26h (22). The specific activities assayed with 5 mM diacetyl at pH 6.0 were 0.29, 11, 0.95, 16, and 5.4 units/mg for mouse, rat, human, hamster, and guinea pig DCXRs, respectively. The diacetyl reductase activities due to the recombinant DCXRs of the five species were purified by ammonium sulfate fractionation and consecutive column chromatographic fractionation on Sephadex G-100, DEAE-Sephacel, and Matrex Red A. The respective yields (amounts) and specific activities of the final preparations purified from each liter of the cultured cells were 55% (0.5 mg) and 130 units/mg for mouse DCXR; 49% (49 mg) and 130 units/mg for rat DCXR; 34% (5 mg) and 15 units/mg for human DCXR; 50% (7.9 mg) and 183 units/mg for hamster DCXR; and 33% (9.0 mg) and 112 units/mg for guinea pig DCXR. For the five DCXR preparations, SDS-PAGE revealed a single protein band (Fig. 2A), and gel exclusion chromatography on a Superdex 200 HR column resulted in a single peak with an apparent Mr of ~100 kDa, demonstrating a tetrameric structure for DCXR.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 2.   SDS-PAGE and Western blot analyses of recombinant DCXRs and L-xylulose reductases purified from hamster and guinea pig livers. A, proteins (2-µg samples) were stained with Coomassie Brilliant Blue R-250 after SDS-PAGE. B, Western blotting analysis using the anti-human DCXR antibody. Lanes: 1, recombinant mouse DCXR; 2, recombinant rat DCXR; 3, recombinant human DCXR; 4, recombinant hamster DCXR; 5, the purified hamster liver enzyme; 6, recombinant guinea pig DCXR; 7, the purified guinea pig liver enzyme: 8, MLCR; and 9, P26h.

The reductase activities of the recombinant DCXRs, except for human DCXR, were gradually lost when they were incubated at 0 °C in 0.1 M phosphate buffer, pH 7.0 (Fig. 3A). This cold inactivation was reversible as shown in a representative result with mouse DCXR (Fig. 3B), in which the enzyme activity was almost completely recovered by incubation of the inactivated DCXR at above 15 °C. The Superdex 200 HR gel exclusion analysis at 4 °C revealed that most of the hamster DCXR molecules inactivated at 0 °C for 1 h were converted into the dimer form (data not shown). The addition of 2 M glycerol, 1 M propyleneglycol, or 0.1 mM NADP+ resulted in almost complete protection against cold inactivation. The enzymes could be stored without any loss of activity for 3 months at -20 °C by adding 20% glycerol.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 3.   Cold inactivation of DCXR. A, time course of inactivation at 0-1 °C. Enzymes: recombinant DCXRs of mouse (), rat (open circle ), hamster (black-triangle), and human (black-square), and the hepatic enzymes of hamster () and guinea pig (triangle ). B, temperature-dependent reactivation of mouse DCXR that had been inactivated in an ice bath for 1 h. Temperature ( °C): 5 (), 10 (black-square), 15 (triangle ), 20 (black-triangle), 25 (diamond ), and 30 (). The relative activity is expressed as the percentage of the activity before cooling.

The diacetyl reductase activities of the DCXRs of the five species showed similar pH dependences: These activities decreased by increasing the pH from 5.8 to 9.0 and exhibited about 40% of their maximum at pH 7.0. The enzymes efficiently reduced other aliphatic and alicyclic compounds with conjugated dicarbonyl (alpha -dicarbonyl) groups, which are listed in Table II, but were inactive toward 1 mM 2,4-pentanedione, 2,5-hexanedione, and 1,4-cyclohexanone that do not have alpha -dicarbonyl groups. The enzymes slowly reduced acetoin and propioin that correspond to the reduced products of diacetyl and 3,4-hexanedione, respectively, but no significant activity was observed for 1 mM concentrations of other monocarbonyl compounds (acetone, cyclohexanone, indan-1-one, pyridine-3-aldehyde, and pyridine-4-aldehyde), 50 µM 3-oxoandrostanes, and 0.1 mM menadione, most of which are good substrates for MLCR and P26h (22). The Km, kcat, and kcat/Km values for the substrates were similar among the four rodent DCXRs, and the kcat/Km values for most substrates of the human DCXR were comparable to those of the rodent DCXRs, although the human Km and kcat values were low. All the DCXRs utilized both NADPH and NADH as coenzymes and showed much lower Km and higher kcat/Km values for NADPH than for NADH.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Substrate specificitiy for carbonyl compounds of rodent and human DCXRs
The kinetic constants were determined at pH 7.0. The kcat value was calculated with the subunit molecular weight of 26,000.

Because the above substrates, except diacetyl (31), acetoin (32), and isatin (33), are not present in mammalian tissues, other endogenous carbonyl compounds were tested as the substrates for DCXR. Methylglyoxal (34) and 3-deoxyglucosone (35) are endogenous dicarbonyl compounds implicated in glycation, but methylglyoxal was reduced at low efficiency (Table II) and the rates for 3-deoxyglucosone (2 mM) were 1-2% of the diacetyl reductase activities of the respective DCXRs. To our surprise, DCXR exerted reductase activity toward ketoses and aldoses with carbon chains from 3 to 5, of which L-xylulose was the best substrate, showing the highest kcat/Km values (Table III). DCXR showed no significant activity for 20 mM aldopentoses (L-arabinose, L- and D-xyloses, and D-ribose), 50 mM hexoses (D-fructose, L-sorbose, D-glucose, and D-galactose), and 10 mM uronates (D-glucuronate and D-2-ketogulonate). When various alcohols were tested as the substrates in the reverse reaction with NADP+ as the coenzyme, all the DCXRs moderately oxidized xylitol and D-threitol, but were inactive toward 50 mM tetriols (meso-erythritol and L-threitol), pentitols (ribitol and L-arabitol), and hexitols (D-sorbitol, D-mannitol, and D-galactitol). It should be noted that MLCR and P26h did not exhibit significant oxidoreductase activity for all the above monosaccharides. DCXR also exhibited a coenzyme preference for NADP+ over NAD+ in the dehydrogenase reaction.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Substrate specificity for monosaccharides in the reduction and dehydrogenation reactions catalyzed by rodent and human DCXRs at pH 7.0

The reductase activity of DCXR was inhibited by short-chain fatty acids (Table IV), of which n-butyric acid showed the highest inhibitory potency. The inhibition patterns of n-butyric acid examined with hamster DCXR were uncompetitive with respect to both NADPH and diacetyl in the forward reaction and were uncompetitive with respect to NADP+ and competitive with respect to xylitol (Ki value = 25 µM) in the reverse reaction. n-Butyric acid (1 mM) did not inhibit the reductase activity of MLCR and P26h, suggesting that it is a specific DCXR inhibitor, which binds to the enzyme-NADP+-alcohol complex.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Inhibition of DCXRs by short-chain fatty acids and their derivatives
The activity was assayed at pH 7.0 in the absence or presence of different concentrations of the inhibitor, and the IC50 value (concentration required for 50% inhibition) was determined.

The above substrate specificity for alpha -dicarbonyl compounds and the ability to catalyze the oxidoreduction between xylitol and L-xylulose suggested that DCXR is identical with both diacetyl reductase and L-xylulose reductase. To test this hypothesis, the activities of diacetyl reductase and L-xylulose reductase were co-purified from liver cytosols of hamster and guinea pig, from which the two enzymes were previously purified (21, 26). As shown in Table V, the two enzyme activities were detected in the cytosols of the two animal livers, and more than 90% of the activities were inhibited by 1 mM n-butyric acid. In the first column chromatography on Sephadex G-100, a minor diacetyl reductase activity of about 35 kDa, which is attributed to aldehyde and carbonyl reductases (21), was separated from the major enzyme peak (of about 100 kDa) that was co-eluted with an L-xylulose reductase activity. The two enzyme activities in the high molecular weight activity peaks of the two animal livers were also co-migrated in the subsequent purification steps, in which their activity ratios were essentially constant. The final enzyme preparations from the two animal livers were homogeneous on SDS-PAGE, showing the same molecular weights as the respective recombinant enzymes (Fig. 2A), and reacted with the anti-human DCXR antibody on Western blot analysis (Fig. 2B). The amino acid sequences of peptides derived from the purified enzymes of hamster and guinea pig livers completely matched the regions of the amino acid sequences deduced from the cDNAs for hamster and guinea pig DCXRs (Fig. 1). In addition, the purified hepatic enzymes showed almost the same substrate specificity for carbonyl compounds as those of the respective recombinant DCXRs. For example, the Km values for 1,4-dibromo-2,3-butanedione, 2,3-hexanedione, and L-xylulose were 5.6, 91, and 220 µM, respectively, for the hamster liver enzyme, and the same values for the guinea pig liver enzyme were 9.2, 180, and 270 µM. The L-xylulose reductase activities in the cytosols of mouse and rat livers were 4.5 and 28 milliunits/mg, respectively, and were inhibited by 1 mM n-butyric acid, although the enzymes were not purified. The data clearly indicate that DCXR is identical with both diacetyl reductase and L-xylulose reductase.

                              
View this table:
[in this window]
[in a new window]
 
Table V
Co-purification of diacetyl reductase and L-xylulose reductase activities from hamster and guinea-pig liver cytosols
The reductase activities for 5 mM diacetyl (DR) and 1.0 mM L-xylulose (XR) were assayed at pH 6.0.

Tissue Distribution-- The tissue distribution of the DCXR mRNA was initially assessed by RT-PCR. As illustrated in Fig. 4a, we detected the expression of DCXR transcript in various tissues of human and four rodent species. The high level of the transcript in kidney was common to all these species, although the expression levels in the other tissues seemed to be different depending on the species. The tissue distribution patterns of the DCXR transcript almost correlated with the results of Western blot analysis using anti-human DCXR polyclonal antibody, which cross-reacted with rodent DCXRs, but not with MLCR and P26h (Fig. 2B). The immunopositive protein bands in the liver and kidney of all the animals were relatively strong, but were weak in other tissues (Fig. 4c). The results suggest that DCXR, although it is ubiquitously distributed in mammalian tissues, is expressed highly in kidney and liver.


View larger version (58K):
[in this window]
[in a new window]
 
Fig. 4.   Tissue distribution of DCXR and its mRNA. a, RT-PCR analysis for expression of mRNAs for rodent and human DCXRs. b, RT-PCR analysis for expression of mRNAs for mouse, rat, and human beta -actins. c, Western blotting analysis using the anti-mouse DCXR antibody for the mouse and rat tissues or with the anti-human DCXR antibody for the other rodent and human tissues. Tissues: Br, brain; Lu, lung; He, heart; Li, liver; Ki, kidney; Sp, spleen; Te, testis; and Ep, epididymis. PC (positive control).

Immunohistochemical and Cytochemical Localization of DCXR in Kidney-- The localization of DCXR in mouse and rat kidneys was examined by immunohistochemical staining with the anti-mouse DCXR antibody, which cross-reacted with rat DCXR. In a BALB/c mouse kidney section, the immunostaining was predominant at the brush border of the proximal tubules and was not evident in the distal tubules and in the collecting duct and staining was absent in the glomeruli (Fig. 5, a and c). In a Sprague-Dawley rat kidney section, the immunopositive reaction was mainly observed in the distal tubules and the collecting duct (Fig. 5d) but again was not evident in the glomeruli (data not shown). The sequential rat kidney section was also stained using the monoclonal antibody 6D12 that is known to react with carboxymethyllysine, one of the major AGEs found in diabetic patients (36), to test the possibility of whether carboxymethyllysine and DCXR are co-distributed. The immunostaining for carboxymethyllysine was positive at the collecting duct (Fig. 5e), and its co-localization with DCXR was demonstrated by the double staining (Fig. 5f).


View larger version (89K):
[in this window]
[in a new window]
 
Fig. 5.   Immunohistochemical staining of DCXR in kidneys of mouse and rat. The BALB/c mouse kidney sections were stained with the anti-mouse DCXR antibody (a and c) and the preimmune rabbit IgG (b). The Sprague-Dawley rat kidney sections were stained with the antibody (d) and the monoclonal anti-AGE antibody, 6D12 (e), and the two stained sections are superimposed (f). The immunoreactive staining colors are pink (a), green (c), red (d), and green (e). PT, proximal tubule; DT, distal tubule; CD, collecting duct; G, glomerulus. Bars = 10 µm.

Finally, the mouse kidney sections were stained with the anti-mouse DCXR antibody and the anti-rabbit IgG gold complex, and the immunochemically stained preparations were then analyzed by electron microscopy. Extensive labeling by gold particles was seen in the microvilli of the inner wall of the proximal tubules (Fig. 6) and in the distal tubules with less intensity (data not shown).


View larger version (177K):
[in this window]
[in a new window]
 
Fig. 6.   Ultrastructural localization of DCXR in epithelial cells of mouse renal tubule by immunogold staining. Note that extensive labeling was observed in the brush-border membranes of a proximal renal tubule in a longitudinal section stained with the anti-DCXR antibody (a) but not in a section stained with the preimmune rabbit IgG (b). Bar = 500 nm.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The present cloning and expression of a cDNA encoding DCXR, which is enriched in mouse kidney, together with the molecular characterization of human, rat, hamster, and guinea pig counterparts, indicate that the protein belongs to the SDR superfamily and exhibits both diacetyl reductase and L-xylulose reductase activities, which are distinct from the substrate specificity of MLCR and P26h (22). The sequences of the rodent DCXRs are the first report of these to our knowledge, but the sequence of our human DCXR is identical to that of P34H (27), which is thought to be involved in sperm-zona pellucida interaction, except for one amino acid substitution at position 239. Because the amino acid substituted in P34H is outside the substrate-binding site in our ongoing structural determination of human DCXR crystal2 and may not cause large changes of its enzymatic properties, human DCXR and P34H are probably the same protein. The tissue distribution of DCXR and its mRNA suggests general roles for P34H or DCXR in the metabolism of dicarbonyl compounds and glucose rather than its epididymis-specific function (27). In fact, no abnormality in fertilization was observed in mice lacking the dcxr gene.3 Furthermore, the deficiency of L-xylulose reductase, which is demonstrated here to be identical with DCXR, has been known to result in essential pentosuria, and individuals with this disorder are normal at least in their reproductive function, as has been demonstrated in a family study of the pentosuria allele (37, 38). In terms of a genetic disorder, the identification of the variant gene resulting in essential pentosuria will be an important study in the future.

Dicarbonyl compounds are substrates for monomeric aldo-keto reductases (10, 11, 39) and carbonyl reductase (40), as well as dimeric dihydrodiol dehydrogenase (11) and sepiapterine reductase (41), in addition to tetrameric diacetyl reductase (21, 42, 43) purified from animal tissues. Of these enzymes, diacetyl reductase resembles DCXR with respect to the tetrameric structure, pH optimum, and substrate specificity, including the kinetic constants for various carbonyl compounds. The cold inactivation of recombinant rodent DCXRs is also similar to the reports that diacetyl reductases of bovine and pigeon are unstable at 4 °C (42, 43). In fact, we demonstrate here the identity of DCXR and diacetyl reductase by their co-purification from hamster and guinea pig livers. In addition, the results of the present study emphasize that diacetyl reductase and L-xylulose reductase, which have been classified as distinct enzymes in the Enzyme Nomenclature system, are identical. The recombinant DCXRs, i.e. diacetyl reductases, efficiently reduced L-xylulose, and catalyzed its reverse reaction, xylitol dehydrogenation, showing the Km values for the sugars similar to those of L-xylulose reductases partially purified from guinea pig liver (26, 44, 45) and from human erythrocytes of normal individuals without the pentosuria allele (38). The identity of the two enzymes was here demonstrated by their co-purification from hamster and guinea pig livers. The cold inactivation of guinea pig DCXR may account for the instability of guinea pig liver L-xylulose reductase reported in previous studies (44, 45). The inhibition of L-xylulose reductase activity in the liver cytosols of mouse and rat by the specific DCXR inhibitor, n-butyric acid, also suggests the identity of the two enzymes in the two animal species. In aqueous solutions, between 8 and 20% of the L-xylulose probably exists in the free ketose/chain form based on the percentage of its enantiomer that is in the chain form (46). Because DCXR reduced aliphatic dicarbonyl compounds and oxidized xylitol that does not cyclize, the enzyme acts on the chain form of L-xylulose in the forward direction, and the true Km values for L-xylulose may be much lower than the apparent values estimated.

DCXRs oxidized D-threitol, as well as xylitol, of the sugar alcohols tested. Based on the chemical reaction between L-xylulose and xylitol, which was catalyzed by the enzymes, the oxidized product of D-threitol is D-threose or D-erythrulose. However, neither the D- nor the L-form of threose serves as the best substrate for the DCXRs. Although D-erythrulose, which is not commercially available, was not tested as a substrate in this study, it is structurally similar to L-xylulose and would most likely be a good substrate for the enzyme. The enzyme that catalyzes the reversible reaction between D-erythrulose and D-threitol is called D-erythrulose reductase (EC 1.1.1.162), and the enzyme purified from chicken liver (47) has been reported to show substrate specificity for aliphatic alpha -dicarbonyl compounds similar to those of animal diacetyl reductases (21, 42, 43) and the mammalian DCXRs characterized in this study. In addition, D-erythrulose reductase of bovine liver shows cold inactivation and reduces some other tetroses and pentoses at low rates (48). Furthermore, the amino acid sequence of the chicken liver enzyme4 is similar to those of the mammalian DCXRs (about 78% sequence identity). Thus, diacetyl reductase, L-xylulose reductase, and, possibly, D-erythrulose reductase are the same enzyme. Although the metabolic pathways for forming diacetyl and D-erythrulose in mammals are not known, L-xylulose reductase is an enzyme of the uronate cycle, which accounts for about 5% of the total glucose catabolism per day in man (49). In this respect, the three enzymes should be named L-xylulose reductase.

The tissue distribution analysis revealed that DCXR is a ubiquitous protein, although it is highly expressed in liver and kidney. This supports the general function of the enzyme in the uronate cycle. As previously suggested for diacetyl reductase (21), DCXR also acts as a detoxification enzyme toward reactive dicarbonyl compounds, which are formed in the tissue or ingested as components of foods and beverages (32). In addition, the co-distribution of DCXR and carboxymethyllysine in the renal tubules led us to speculate that DCXR may interact with the dicarbonyl precursors of AGEs. DCXR moderately reduced methylglyoxal and threoses, which have been shown to be involved in AGE formation (34) and the generation of superoxide anions (50), respectively. Alternatively, DCXR may play a role in the production of xylitol, an intracellular organic osmolyte, in the cells of the renal tubules and collecting ducts. In the kidney, several intracellular organic osmolytes, including sorbitol are known, and aldose reductase, the enzyme that produces sorbitol from glucose, is abundant in the renal medulla (51) and implicated in osmoregulation in this tissue (52). Glucose is metabolized by the uronate cycle that includes DCXR more abundantly than by the polyol pathway, in which aldose reductase constitutes the first and rate-limiting step because of its high Km value for glucose. Xylitol has been shown to have a low transepithelial permeability in the airway surface of the lung and acts as an osmolyte (53). The present finding that DCXR is localized in the brush-border membranes of renal tubular cells suggests that the local accumulation of the osmolyte xylitol in the membrane is responsible for water reabsorption in the proximal tubules. In addition, xylitol formation by the enzyme would contribute to cellular osmoregulation against osmolytic stress in the distal tubules and collecting ducts. Although pentosuric individuals are clinically healthy apart from their chronic excretion of L-xylulose (37), some disorders in the metabolism of dicarbonyl compounds and renal function may be gleaned from the proposed roles of DCXR, which will be tested by generating transgenic and knockout animals of the dcxr gene.

    ACKNOWLEDGEMENTS

We are grateful to Drs. Kenichi Matsubara and Kousaku Okubo for guidance in the body map profiling in the initial part of this work.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) D89656, AB061719, AB061720, AB045204, and AB013846.

§ To whom correspondence should be addressed. Tel.: 81-48-669-3026; Fax: 81-48-652-7254; E-mail: junichi.nakagawa@po.rd.taisho. co.jp.

Published, JBC Papers in Press, March 6, 2002, DOI 10.1074/jbc.M110703200

2 O. El-Kabbani, S. Ishikura, and A. Hara, unpublished observation.

3 Y. Uematsu, N. Tada, and J. Nakagawa, unpublished observation.

4 M. Maeda, personal communication.

    ABBREVIATIONS

The abbreviations used are: AGE, advanced glycation endproduct; MLCR, mouse lung carbonyl reductase; SDR, short-chain dehydrogenase/reductase; DCXR, dicarbonyl/L-xylulose reductase; RT-PCR, reverse transcription-PCR; EST, expressed sequence tag; RACE, rapid amplification of cDNA ends; RT, room temperature; P26h, hamster sperm 26-kDa protein; P34H, human sperm 34-kDa protein; PBS, phosphate-buffered saline.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Sell, D. R., and Monnier, V. M. (1990) J. Clin. Invest. 85, 380-384[Medline] [Order article via Infotrieve]
2. Makita, Z, Radoff, S., Rayfield, E. J., Yang, Z., Skolnik, E., Delaney, V., Friedman, E. A., Cerami, A., and Vlassara, H. (1991) N. Engl. J. Med. 325, 836-842[Abstract]
3. Weiss, M. F., Erhard, P., Kader-Attia, F. A., Wu, Y. C., Deoreo, P. B., Araki, A., Glomb, M. A., and Monnier, V. M. (2000) Kidney Int. 57, 2571-2585[CrossRef][Medline] [Order article via Infotrieve]
4. Raj, D. S., Choudhury, D., Welbourne, T. C., and Levi, M. (2000) Am. J. Kidney Dis. 35, 365-380[Medline] [Order article via Infotrieve]
5. Bucala, R., Makita, Z., Vega, G., Grundy, S., Koschinsky, T., Cerami, A., and Vlassara, H. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6434-6438[Abstract/Free Full Text]
6. Schmidt, A. M., Vianna, M., Gerlach, M., Brett, J., Ryan, J., Kao, J., Esposito, C., Hegarty, H., Hurley, W., Clauss, M., Wang, F., Pan, Y.-C. E., Tsang, T. C., and Stern, D. (1992) J. Biol. Chem. 267, 14987-14997[Abstract/Free Full Text]
7. Horiuchi, S., Murakami, M., Takata, K., and Morino, Y. (1986) J. Biol. Chem. 261, 4692-4696
8. Dyer, D. G., Dunn, J. A., Thorpe, S. R., Bailie, K. E., Lyons, T. J., McCance, D. R., and Baynes, J. W. (1993) J. Clin. Invest. 91, 2463-2469[Medline] [Order article via Infotrieve]
9. Hammes, H. P., Martin, S., Federin, K., Geisen, K., and Brownlee, M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 11555-11558[Abstract/Free Full Text]
10. Feather, M. S., Flynn, T. G., Munro, K. A., Kubiseski, T. J., and Walton, D. J. (1995) Biochim. Biophys. Acta 197, 373-379
11. Sato, K., Inazu, A., Yamaguchi, S., Nakayama, T., Deyashiki, Y., Sawada, H., and Hara, A. (1993) Arch. Biochem. Biophys. 307, 286-294[CrossRef][Medline] [Order article via Infotrieve]
12. Makita, Z., Bucala, R., Rayfield, E. J., Friedman, E. A., Kaufman, A. M., Korbet, S. M., Barth, R. H., Winston, J. A., Fuh, H., Manogue, K. R., Cerami, A., and Vlassara, H. (1994) Lancet 343, 1519-1522[CrossRef][Medline] [Order article via Infotrieve]
13. Gugliucci, M., and Bendayan, M. (1996) Diabetologia 39, 149-160[CrossRef][Medline] [Order article via Infotrieve]
14. Nakanishi, M., Deyashiki, Y., Ohshima, K., and Hara, A. (1995) Eur. J. Biochem. 228, 381-387[Medline] [Order article via Infotrieve]
15. Jörnvall, H., Persson, B., Krook, M., Atrian, S., González-Duarte, R., Jeffery, J., and Ghosh, D. (1995) Biochemistry 34, 6003-6013[CrossRef][Medline] [Order article via Infotrieve]
16. Touster, O., Reynolds, V. H., and Hutcheson, R. M. (1954) J. Biol. Chem. 221, 697-709
17. Grant, M. E., Harwood, R., and Williams, I. F. (1975) Eur. J. Biochem. 54, 531-540[Medline] [Order article via Infotrieve]
18. Okubo, K., Hori, N., Matoba, R., Niiyama, T., Fukushima, A., Kojima, Y., and Matsubara, K. (1992) Nat. Genet. 2, 173-179[CrossRef][Medline] [Order article via Infotrieve]
19. Takenaka, M., Imai, E., Kaneko, T., Ito, T., Moriyama, T., Yamauchi, A., Hori, M., Kawamoto, S., and Okubo, K. (1998) Kidney Int. 53, 562-572[CrossRef][Medline] [Order article via Infotrieve]
20. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed. , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
21. Hara, A., Seiriki, K., Nakayama, T., and Sawada, H. (1985) in Enzymology of Carbonyl Metabolism 2: Aldehyde Dehydrogenase, Aldo-keto Reductase, and Alcohol Dehydrogenase (Flynn, T. G. , and Weiner, H., eds) , pp. 291-304, Alan R. Liss Inc., New York
22. Ishikura, S., Usami, N., Kitahara, K., Isaji, T., Oda, K., Nakagawa, J., and Hara, A. (2001) Biochemistry 40, 214-224[CrossRef][Medline] [Order article via Infotrieve]
23. Hsu, S. M., Raine, L., and Fanger, H. (1981) Am. J. Clin. Pathol. 75, 816-821[Medline] [Order article via Infotrieve]
24. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
25. Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve]
26. Arsenis, C., and Touster, O. (1969) J. Biol. Chem. 244, 3895-3899[Abstract/Free Full Text]
27. Légaré, C., Gaudreault, C., St-, Jacques, S., and Sullivan, R. (1999) Endocrinology 140, 3318-3327[Abstract/Free Full Text]
28. Gaudreault, C., Légaré, C., Bérubé, B., and Sullivan, R. (1999) Biol. Reprod. 61, 264-273[Abstract/Free Full Text]
29. Tanaka, N., Nonaka, T., Nakanishi, M., Deyashiki, Y., Hara, A., and Mitsui, Y. (1996) Structure 4, 33-45[Medline] [Order article via Infotrieve]
30. Tanaka, N., Nonaka, T., Nakamura, K. T., and Hara, A. (2001) Cur. Org. Chem. 5, 89-111
31. Otsuka, M., and Ohmori, S. (1992) J. Chromatogr. 577, 215-220[Medline] [Order article via Infotrieve]
32. Otsuka, M., Mine, T., Ohuchi, K., and Ohmori, S. (1996) J. Biochem. (Tokyo) 119, 246-251[Abstract/Free Full Text]
33. Medvedev, A. E., Clow, A., Sandler, M., and Glover, V. (1996) Biochem. Pharmacol. 52, 385-391[CrossRef][Medline] [Order article via Infotrieve]
34. Thornalley, P. J. (1996) Gen. Pharmacol. 27, 567-573
35. Niwa, T. (1999) J. Chromatogr. 731, 23-36[CrossRef][Medline] [Order article via Infotrieve]
36. Tanji, N., Markowitz, G. S., Fu, C., Kislinger, T., Taniguchi, A., Pischetsrieder, M., Stern, D., Schmidt, A. M., and D'Agati, V. D. (2000) J. Am. Soc. Nephrol. 11, 1656-1666[Abstract/Free Full Text]
37. Wang, Y. M., and van Eys, J. (1970) N. Eng. J. Med. 282, 892-896[Medline] [Order article via Infotrieve]
38. Lane, A. B. (1985) Biochem. Genet. 23, 61-72[CrossRef][Medline] [Order article via Infotrieve]
39. O'connor, T., Ireland, L. S., Harrison, D. J., and Hayes, J. D. (1999) Biochem. J. 343, 487-504[CrossRef][Medline] [Order article via Infotrieve]
40. Hara, A., Deyashiki, Y., Nakayama, T., and Sawada, H. (1983) Eur. J. Biochem. 133, 207-214[Medline] [Order article via Infotrieve]
41. Sueoka, T., and Kato, S. (1985) Biochim. Biophys. Acta 843, 193-198[Medline] [Order article via Infotrieve]
42. Bernardo, A., Prieto, J. G., and Samiento, R. M (1984) Int. J. Biochem. 16, 1065-1070[CrossRef][Medline] [Order article via Infotrieve]
43. Provecho, F., Burgos, J., and Sarmiento, R. M. (1984) Int. J. Biochem. 16, 423-427[CrossRef][Medline] [Order article via Infotrieve]
44. Hickman, J., and Ashwell, G. (1958) J. Biol. Chem. 234, 758-761
45. Hollman, S. (1959) Hoppe-Seylers Z. Physiol. Chem. 317, 193-216[Medline] [Order article via Infotrieve]
46. Hayward, L. D., and Angyal, S. T. (1977) Carbohydr. Res. 53, 13-20
47. Maeda, M., Hosomi, S., Mizoguchi, T., and Nishimura, T. (1998) J. Biochem. (Tokyo) 123, 602-606[Abstract/Free Full Text]
48. Uehara, K., Tanimoto, T., and Sato, H. (1974) J. Biochem. (Tokyo) 75, 333-345[Abstract/Free Full Text]
49. Winegrad, A., Clements, R. S., Jr., Beisswender, P. S., and Burden-Russell, C. L. (1967) in International Symposium on Metabolism, Physiology, and Clinical Use of Pentoses and Polyols (Horecker, B. L. , Lang, K. , and Takagi, Y., eds) , pp. 258-274, Springer-Verlag, New York
50. Ortwerth, B. J., James, H., Simpson, G., and Linetsky, M. (1998) Biochem. Biophys. Res. Commun. 245, 161-165[CrossRef][Medline] [Order article via Infotrieve]
51. Dvornil, D. (1987) Aldose Reductase Inhibition: An Approach to the Prevention of Diabetic Complications , pp. 222-323, McGraw-Hill, New York
52. Burg, M. B. (1988) Kidney Int. 33, 635-641[Medline] [Order article via Infotrieve]
53. Zebner, J., Seiler, M. P., Launspach, J. L., Karp, P. H., Kearney, W. R., Look, D. C., Smith, J. J., and Welsh, M. J. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 11614-11619[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Toxicol SciHome page
J. B. Morris and A. F. Hubbs
Inhalation Dosimetry of Diacetyl and Butyric Acid, Two Components of Butter Flavoring Vapors
Toxicol. Sci., March 1, 2009; 108(1): 173 - 183.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. H. Cho-Vega, S. Tsavachidis, K.-A. Do, J. Nakagawa, L. J. Medeiros, and T. J. McDonnell
Dicarbonyl/L-Xylulose Reductase: A Potential Biomarker Identified by Laser-Capture Microdissection-Micro Serial Analysis of Gene Expression of Human Prostate Adenocarcinoma
Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2615 - 2622.
[Abstract] [Full Text] [PDF]


Home page
Appl. Environ. Microbiol.Home page
N. Nair and H. Zhao
Biochemical Characterization of an L-Xylulose Reductase from Neurospora crassa
Appl. Envir. Microbiol., March 15, 2007; 73(6): 2001 - 2004.
[Abstract] [Full Text] [PDF]


Home page
Appl. Environ. Microbiol.Home page
J. S. Aarnikunnas, A. Pihlajaniemi, A. Palva, M. Leisola, and A. Nyyssola
Cloning and Expression of a Xylitol-4-Dehydrogenase Gene from Pantoea ananatis
Appl. Envir. Microbiol., January 1, 2006; 72(1): 368 - 377.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
S. Ishikura, N. Usami, M. Araki, and A. Hara
Structural and Functional Characterization of Rabbit and Human l-Gulonate 3-Dehydrogenase
J. Biochem., March 1, 2005; 137(3): 303 - 314.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/20/17883    most recent
M110703200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakagawa, J.
Right arrow Articles by Kitamura, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakagawa, J.
Right arrow Articles by Kitamura, K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement